Literature DB >> 1365446

The MPTP-treated mouse as a model of parkinsonism: how good is it?

R E Heikkila1, P K Sonsalla.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1365446     DOI： 10.1016/0197-0186(92)90256-q

Source DB:  PubMed          Journal:  Neurochem Int        ISSN： 0197-0186            Impact factor:   3.921


× No keyword cloud information.
  16 in total

1.  WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

Authors:  David A Price; Alex A Martinez; Alexandre Seillier; Wouter Koek; Yolanda Acosta; Elizabeth Fernandez; Randy Strong; Beat Lutz; Giovanni Marsicano; James L Roberts; Andrea Giuffrida
Journal:  Eur J Neurosci       Date:  2009-05-21       Impact factor: 3.386

Review 2.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

3.  Modeling a sensitization stage and a precipitation stage for Parkinson's disease using prenatal and postnatal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administration.

Authors:  G Muthian; V Mackey; J King; C G Charlton
Journal:  Neuroscience       Date:  2010-06-09       Impact factor: 3.590

4.  Melatonin fails to protect against long-term MPTP-induced dopamine depletion in mouse striatum.

Authors:  C J van der Schyf; K Castagnoli; S Palmer; L Hazelwood; N Castagnoli
Journal:  Neurotox Res       Date:  2000-04       Impact factor: 3.911

5.  Nur(R1)turing a notion on the etiopathogenesis of Parkinson's disease.

Authors:  Howard J Federoff
Journal:  Neurotox Res       Date:  2009-04-24       Impact factor: 3.911

6.  A single intramuscular injection of rAAV-mediated mutant erythropoietin protects against MPTP-induced parkinsonism.

Authors:  A Dhanushkodi; E O Akano; E E Roguski; Y Xue; S K Rao; S G Matta; T S Rex; M P McDonald
Journal:  Genes Brain Behav       Date:  2012-11-28       Impact factor: 3.449

Review 7.  Animal models of Parkinson's disease: limits and relevance to neuroprotection studies.

Authors:  Erwan Bezard; Zhenyu Yue; Deniz Kirik; Maria Grazia Spillantini
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

Review 8.  The Path to Progress Preclinical Studies of Age-Related Neurodegenerative Diseases: A Perspective on Rodent and hiPSC-Derived Models.

Authors:  Gabriella MacDougall; Logan Y Brown; Boris Kantor; Ornit Chiba-Falek
Journal:  Mol Ther       Date:  2021-01-09       Impact factor: 11.454

9.  The I2020T Leucine-rich repeat kinase 2 transgenic mouse exhibits impaired locomotive ability accompanied by dopaminergic neuron abnormalities.

Authors:  Tatsunori Maekawa; Sayuri Mori; Yui Sasaki; Takashi Miyajima; Sadahiro Azuma; Etsuro Ohta; Fumiya Obata
Journal:  Mol Neurodegener       Date:  2012-04-25       Impact factor: 14.195

10.  A Guide to the Generation of a 6-Hydroxydopamine Mouse Model of Parkinson's Disease for the Study of Non-Motor Symptoms.

Authors:  Débora Masini; Carina Plewnia; Maëlle Bertho; Nicolas Scalbert; Vittorio Caggiano; Gilberto Fisone
Journal:  Biomedicines       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.